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system and eyes. Lack of vaccine and other effective prophylactic measures coupled with the 23 largely asymptomatic nature and unrare clinical treatment failure calls for development of new 24 antichlamydials, particularly selective antichlamydials without adverse effects on humans and 25 the beneficial microbiota. We previously reported that benzal-N-acylhydrazones (BAH) can 26 inhibit chlamydiae without detectable adverse effects on host cells and beneficial lactobacilli that 27 dominate the human vaginal microbiota among reproductive-age women. However, the 28 antichlamydial mechanism of BAH is not known. Whereas 4 single nucleotide polymorphisms 29 (i.e., SNP1-4) were identified in a rare Chlamydia variant with a low level of BAH resistance, 30 termed MCR, previous studies failed to establish a causal effect of any particular SNP(s). In the 31 present work, we performed recombination to segregate the four SNPs. Susceptibility tests 32 indicate that the R51G GrgA allele is both necessary and sufficient for the low level of BAH 33 resistance. Thus, the Chlamydia-specific transcription factor GrgA either is a direct target of 34 BAH or regulates BAH susceptibility. We further confirm an extremely low rate of BAH 35 resistance in Chlamydia. Our findings warrant exploration of GrgA as a therapeutic and 36 prophylactic target for chlamydial infections. 37 38 INTRODUCTION 4 lead to problems ranging from severe diarrhea to increased risks for serious but not immediately 62 noticeable metabolic changes [18, 19] . Second, although in culture C. trachomatis is highly 63 susceptible to the therapeuticals, clinical treatment failure, which leads to persistent infection, is 64 not rare [20, 21] . Finally, given the fact that tetracycline resistance has become widespread in C. 65 suis due to farmers' use of tetracycline as a growth promoter [22] [23] [24] , antibiotic resistance could 66 emerge in other Chlamydia species including C. trachomatis and C. pneumoniae. 67
For the above-mentioned reasons, it is important to identify new antichlamydial leads, 68 particularly selective antichlamydial leads without adverse effects on either the host or other 69 microbes, and identify their antichlamydial mechanisms. We have reported benzal-N-70 acylhydrazones (BAH) as novel antichlamydial leads capable of inhibiting all three Chlamydia 71 species tested, C. trachomatis, C. pneumoniae and C. muridarum [25] . Significantly, at 72 concentrations above minimal inhibition concentrations, BAH have no adverse effects on animal 73 cells or vaginal lactobacilli [25] . Another attractive feature of BAH is their extremely low 74 spontaneous mutation rates leading to resistance [25, 26] . Although a C. muridarum variant 75 termed MCR with a low-level of BAH resistance was initially isolated following a lengthy 76 selection process, multiple repeated attempts to isolate additional resistant variants from 77 mutagenized as well as non-mutagenized stocks of C. muridarum and C. trachomatis were 78 unsuccessful [25, 26] . 79
How BAH inhibit chlamydiae remains unknown. Compared to the parental C. muridarum, 80 MCR carries four single nucleotide polymorphisms (i.e., SNP1-4) in its genome (Table 1) . SNP1 81 causes an A228V substitution in the major outer membrane protein (MOMP). Although A228 is 82 conserved in MOMP in C. muridarum and C. trachomatis, V228 is found in C. pneumoniae, 83 which remains highly susceptible to BAH [25]. SNP2 is located at the 10 th position of the 5' 84 5 untranslated region of the mRNA for Npt1 (ATP/ADP translocase), and is associated with a 85 decreased Npt1 mRNA level. BAH have no effect on Npt1-mediated ATP transportation, 86 suggesting that Ntp1 is unlikely a target of BAH [25] . SNP3 causes premature translation 87 termination of TC0412, a homolog of the putative virulence factor CT135 in C. trachomatis 
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Generation of recombinant chlamydiae 122
Mouse L929 cells grown in T25 flasks were coinfected with 2 parental strains at an MOI 123 (multiplicity of infection) of 1 IFU per cell for each strain, cultured with medium containing 1 124 µg/ml cycloheximide. After a passage without antibiotics, they were cultured with 6 ng/ml 125 rifampin plus 25 nM LBM415 or 6 µg/ml spectinomycin (di selection) for 6 passages. 90 µM 126 CF0001 was included as part of tri selection either following the completion of or in parallel to 127 the di selection for 6 passages. 128 129
Generation of clonal populations 130
Clonal populations of parental strains with resistance to rifampin, spectinomycin or LBM415 131 ( (Table 2) We performed two MoPn_Rif R X MCR_LBM R recombination studies. For the first one, we 164 coinfected 5 flasks of L929 cells with the two parental strains, and maintained the flasks as 165 independent lines (W1-5) in subsequent passages ( Fig. 1A ). We selected for recombinant 166 chlamydiae using sub-minimal inhibitory concentrations of rifampin and LBM415 (see 167 experimental procedures). At the end of the 6th passage of the Rif/LBM di selection, Sanger's 168 sequencing revealed that wild-type rpoB and defA alleles were apparently eliminated in 4 of the 169 5 lines ( Fig. 1B) , whereas the W4 line still retained both the wild-type and mutant alleles of rpoB 170 and defA. These results indicate that at this point the W1, W2, W3 and W5 lines were comprised 10 of recombinants and very few (if any) parental organisms ( Fig. 1B) . Contrast to the rpoB and 172 defA selection markers, almost all loci of the 4 SNPs displayed a mixture of wild-type and 173 mutant alleles in these lines ( Fig. 1B) , suggestive of good recombination complexity at most of 174 the SNP loci. Exceptions were apparent absence of S1(A228V MOMP) and S2(wtNpt1) alleles 175 in the W1 and W3 lines, respectively ( Fig. 1B ), likely reflecting low recombination complexity 176 at these sites in these lines. We then continued the selection for BAH resistance by adding 177 CF0001 to the Rif/LBM di selection for 6 additional passages. Interestingly, by the end of the 6 th 178 passage with the Rif/LBM/CF tri selection, we observed apparent elimination of wild-type 179 alleles at all the 4 SNP loci in all 5 lines (Fig. 1C) , even for the locus of S1(MOMP), where the 180 S1(A228V MOMP) allele was unnoticeable (and thus must be present at a very low percentage) 181 prior to the start of the tri selection ( Fig. 1B) . and subjecting them to the Rif/LBM di selection and Rif/LBM/CF tri selection in parallel (as 205 opposed to sequential di and tri selections above) (Fig. 1D ). By the end of 6 th passages with 206 either selection regimen wild-type rpoB and defA alleles were apparently absent, indicating 207 (near) complete elimination of parental chlamydiae (Fig. 1E ). In Rif/LBM-selected populations, 208 both wild-type and mutant alleles were present at most of the SNP loci (Fig. 1E ). In comparison, 209
Rif/LBM/CF-selected populations exhibited only mutant alleles at all the loci (Fig. 1F ). The 210 consistent elimination of chlamydiae carrying any wild-type alleles by CF0001 in both 211 recombination studies suggests two alternative probabilities. In one, all of the 4 mutant alleles in 212 MCR are necessary for BAH resistance. In the other, only 1 or up to 3 of the 4 mutant alleles are 213 necessary, but accompanying mutant allele(s) compensate for growth disadvantages caused by 214 the mutant allele(s) required for BAH resistance. 215
To distinguish between these probabilities, we set out to generate clonal populations from the 216 W1, W2, W3 and W5 lines that were subjected to 6 passages of Rif/LBM di selection through 217 12 either limiting dilution [31] or plaquing [32] . A total of 79 clonal populations were generated. 218
Complete genotyping analyses were performed for 32 populations, which represented only 8 of 219 the 16 possible recombinant genotypes (Table S2 ). The remaining 47 clonal populations were 220 only partially genotyped because initial sequencing data indicated that either they were likely 221 redundant populations or their genotypes were considered unhelpful based on BAH susceptibility 222 data that were already obtained from fully genotyped populations. 223 BAH susceptibility tests were performed for 14 clonal populations, which represented all of 224 the 8 defined unique genotypes, alongside with MCR and MoPn (Fig. 2) . As expected, both all-225
wild-type allele populations tested (i.e., w5c2 and w1c15) displayed susceptibility to CF0001 as 226 wild-type MoPn, whereas both all-mutant-allele populations tested (i.e., w3c2 and w5c4) 227 displayed resistance as MCR. Interestingly, among 10 clonal populations with 1-3 mutant alleles, 228 only w2c10, the sole clonal population with an S4(R51G GrgA) allele, was resistant, whereas all 229 9 other populations, which carried S4(wtGrgA) were susceptible even though they had up to 3 230 mutant alleles at S1(MOMP), S2(Npt1) and/or S3(TC0412). These results suggest that among 231 the 4 SNPs in MCR, only S4(R51 GrgA) is required for BAH resistance. However, due to the 232 coexistence of the S3(t_TC0412) allele in w2c10, and the lack of a population with S4(R51G 233 GrgA) as the only mutant allele, it was unclear whether the R51G GrgA allele alone is sufficient 234 for BAH resistance. In the above MoPn_Rif R X MCR_LBM R recombination studies, the selection markers rpoB 244 and defA are both located between S3(TC0412) and S4(GrgA) in the MoPn genome ( Fig. 1A,  245 D). To obtain variants with a genotype of S1(wtMOMP), S2(wtNpt1), S3(wtTC0412) and 246 S4(R51G GrgA), we decided to use two selection markers separated by a SNP(s). We derived a 247 spectinomycin-resistant C. muridarum variant (MoPn_Spc R ), which carries a single point 248 mutation in the 16S rRNA (Table 3) . Unlike rpoB and defA, the 16S rRNA gene is located 249 between S1(MOMP) and S2(Npt1) (Fig. 3A) . This mutation did not affect inhibition of 250 chlamydiae by CF0001 (Fig. S1) . 251
Initially, we tried to generate but failed to select for MoPn_Spc R X MCR_LBM R 252 recombinants using the Spc/LBM (spectinomycin plus LBM415) selection regimen in 3 different 253 attempts. In the regimen, the concentration of LBM415 was either the same as or higher than the 254 concentration used for the above Rif/LBM regimen. The Spc/LBM regimen failed to eliminate 255 wild-type defA allele although it successfully eliminated wild-type 16S rRNA. These findings 256 suggest that spectinomycin and LBM415 are incompatible for recombinant selection. 257
We next derived an MCR variant with rifampin resistance (MCR_Rif R ). Similar to 258 MoPn_Rif R , which expresses a Q455Y RpoB, MCR_Rif R expresses an S476Y RpoB (Table 3) . 259 MCR_Rif R retained low level of CF0001-resistance as MCR and MCR_LBM415 (Fig. S1 ). 260
We created 6 independent MoPn_Spc R X MCR_Rif R recombinant lines. Each of the 6 lines 261 was subjected to parallel Spc/Rif di selection and Spc/Rif/CF tri selection, and subsequently to 262 14 genotyping analyses (Fig. 3A) . After 6 passages with either selection, most (if not all) parental 263 chlamydiae were eliminated, as indicated by apparent lack of the spectinomycin-susceptible 16S 264 rRNA allele and rifampin-susceptible rpoB allele (Fig. 3B, C) . MoPn_Spc R X MCR_Rif R recombinants (Fig. 3B ) was lower than that of the Rif/LBM-selected 277
MoPn_Rif R X MCR_LBM R recombinants (Fig. 1B) . Although the Spc/Rif di selection displayed 278 no bias for either S1(MOMP) alleles, it showed a consistent bias for the S2(wtNpt1) in all 6 279 lines. It also displayed bias for the S3(t_TC0412) alleles in 3 (r1-3) of the 6 lines. For the 280 S4(GrgA) locus, it displayed bias for (in lines r1 and r3) and against (in line r6) the S4(R51G 281 GrgA) allele, and no apparent bias in the remaining 3 lines (r2, r4 and r5). 282
In a striking contrast to the Rif/LBM/CF-selected MoPn_Rif R X MCR_LBM R recombinants, 283 which consistently carried only mutant alleles at all 4 SNP loci (Fig. 1C) , Spc/Rif/CF-selected 284
MoPn_Spc R X MCR_Rif R recombinants contained both S1(wtMOMP) and/or S3(wtTC0412) 285 15 alleles, in addition to mutant alleles, at the S1(MOMP) and S3(TC0412) loci, but only wild-type 286 allele at the S2(Npt1) locus (Fig. 3C ). The only consistency between Rif/LBM/CF-selected 287 populations and Spc/Rif/CF-selected populations is the lack of wild-type allele at the S4(GrgA) 288 locus (Fig. 3C) , further supporting the notion that the S4(R51G GrgA) allele is necessary for 289 BAH resistance (Fig. 2) . 290
We generated 21 clonal populations from Spc/Rif-selected populations, and 13 clonal 291 populations from Spc/Rif/CF-selected populations. These 34 clonal populations represented 6 of 292 the 16 possible recombinant genotypes (Table S3 ). 12 representative clonal populations were 293 tested for BAH resistance alongside with MCR and MoPn. All 4 clonal populations carrying the 294 S4(wtGrgA) allele demonstrated susceptibility to CF0001, whereas all 8 clonal populations 295 carrying the S4(R51G GrgA) allele including the 3 populations (r8s6, r8s7 and r8s11) carrying 296 S4(R51G GrgA) and wild-type alleles for the 3 remaining SNP loci were resistant (Fig. 3D) . 297
These findings, together with data presented in Fig. 2 , indicate that the S4(R51G GrgA) allele is 298 both necessary and sufficient for BAH resistance, which can be viewed more clearly by 299 arranging all phenotypically characterized clonal populations from both the MoPn_Rif R X 300 MCR_LBM R recombination and the MoPn_Spc R X MCR_Rif R recombination by their S4(GrgA) 301 genotype (Table S4) . 302 303
Ultralow rate of spontaneous BAH resistance 304
Previous studies indicated that BAH resistance in chlamydiae occurs at extremely low rates. 305
The observations that the Rif/LBM/CF selection consistently eliminated wild-type 306 S1(wtMOMP), S2(wtNpt1) and S3(wtTC0412) (Fig. 1C, F ) even though S4(R51G GrgA) is the 307 only mutant allele that is required for BAH resistance suggest that accompanying mutations help 308 16 the survival of chlamydiae carrying S4(R51G GrgA) in the presence of BAH on the background 309 of mutated rpoB and defA. We next determined whether presence of mutant alleles at the 310 S1(MOMP), S2(Npt1) and S3(TC0412) loci in the genome helps selection for variants with 311
GrgA mutation conferring BAH resistance by using the clonal population w3c5, which carries 312 wild-type GrgA allele at the S4(GrgA) locus but mutant alleles at all three remaining SNP loci. 313 A total of 6 screens were carried out with w3c5. The first 2 screens were initiated with a 314 combined 0.9 X 10 7 inclusion-forming units (IFU) of non-mutagenized elementary bodies (EB) 315
and selection was carried out with CF0001 (gradually increased from 80-120 µM) as a sole 316 selection agent. The second 2 screens were initiated with the same number of non-mutagenized 317 EB but selection was carried out with the Rif/LBM/CF tri selection regimen that was used to 318 select for CF0001-resistant recombinants (Fig. 1A, D) . No resistant chlamydiae emerged with 319 either selection regimen. 320
The final two screens for CF0001-resistant variants were initiated with EBs prepared from 321 cultures treated with 2 or 5 mg/ml ethyl methanesulfonate, a DNA-damaging reagent that has 322 been used to mutagenize chlamydiae previously [29, 36, 37] . We also failed to obtain resistant 323 chlamydiae in each of these attempts starting with 2 X 10 7 IFUs of EB. The repeated failures to 324 isolate additional CF0001-resistant variants suggest that only very few and specific mutations in 325
GrgA can lead to BAH resistance and/or sustain chlamydiae. organisms. Therefore, targeting GrgA will provide intrinsically high selectivity. 361
Previous studies have shown that random mutation rates leading to BAH resistance is 362 extremely low in C. trachomatis and C. muridarum. Therefore, MCR represents a rare variant 363 with only a low level of resistance. Consistent elimination of wild-type alleles at the loci of 364 SNP1-3 from Rif/LBM/CF-selected populations suggests that the co-existence of these mutant 365 19 alleles helps survival of chlamydiae carrying the S4(R51G GrgA) allele in the presence of BAH, 366 rifampin and LBM415. Our failures to isolate additional BAH-resistant mutants on the 367 background of S1(A228V MOMP), S2(d_Npt1) and S3(t_TC0412) from clonal population w3c5 368 in multiple attempts with different selection regimen suggest that very few and specific GrgA 369 mutations can cause BAH resistance and/or sustain chlamydial growth. 370
Compared to the prototype antichlamydial BAH CF0001, the recently-developed SF3 has a 371 stronger antichlamydial activity while maintaining non-toxicity to mammalian cells and vaginal 372 lactobacilli [26] . It has been shown previously that MCR can be inhibited completely by SF3 373 even though it is less susceptible than wild-type MoPn to lower concentrations of SF3 [26] . 374
While it is expected that clonal recombinant populations carrying S4(R51G GrgA) as sole 375 mutant allele demonstrate the same properties as MCR, these clonal populations will be more 376 useful for identifying additional selective antichlamydials that interferes with a process involving 377
GrgA. 378
In summary, we have unequivocally established that R51G GrgA is both necessary and 379 sufficient for the low level of BAH resistance in the Chlamydia variant MCR. These findings and 380 the facts that GrgA is a Chlamydia-specific protein and plays important roles in chlamydial 381 transcription indicate GrgA as a promising selective therapeutic/prophylactic target, even though 382 it is unclear whether GrgA is a direct target of BAH or regulates BAH susceptibility without 383 directly interacting with BAH. In addition to the high selectivity, the ultralow rate of BAH 384 resistance in chlamydiae is another super attractive feature for developing BAH compounds as 385 therapeutic/prophylactic agents. 
